Defective cell cycle checkpoints as targets for anti-cancer therapies

Frontiers in Pharmacology

Volumn 3 FEB, Issue , 2012, Pages

  Gabrielli, Brian ^a   Brooks, Kelly ^a   Pavey, Sandra ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Checkpoint; Synthetic lethality; Targeted therapies

Indexed keywords

ANTINEOPLASTIC AGENT; ATM PROTEIN; B RAF KINASE; B RAF KINASE INHIBITOR; BCR ABL PROTEIN; BRCA1 PROTEIN; CAMPTOTHECIN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 INHIBITOR; CHECKPOINT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 2A; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; HISTONE DEACETYLASE INHIBITOR; IMATINIB; IRINOTECAN; PROTEIN P53; PROTEIN SERINE THREONINE KINASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CELL CYCLE ARREST; CELL CYCLE CHECKPOINT; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL FUNCTION; CELL PROLIFERATION; CELL STRESS; CHRONIC MYELOID LEUKEMIA; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; EXCISION REPAIR; GENOTOXICITY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MOLECULARLY TARGETED THERAPY; MONOTHERAPY; NONHUMAN;

EID: 84865971493     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2012.00009     Document Type: Article

References (52)

1. Ashworth, A. (2008). A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J. Clin. Oncol. 26, 3785-3790.
2. Astsaturov, I., Ratushny, V., Sukhanova, A., Einarson, M. B., Bagnyukova, T., Zhou, Y., Devarajan, K., Silverman, J. S., Tikhmyanova, N., Skobeleva, N., Pecherskaya, A., Nasto, R. E., Sharma, C., Jablonski, S. A., Serebriiskii, I. G., Weiner, L. M., and Golemis, E. A. (2010). Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci. Signal. 3, ra67.
3. Auclair,Y., Rouget, R., and Drobetsky, E. A. (2009). ATR kinase as master regulator of nucleotide excision repair during S phase of the cell cycle. Cell Cycle 8, 1865-1871.
4. Azorsa, D. O., Gonzales, I. M., Basu, G. D., Choudhary, A., Arora, S., Bisanz, K. M., Kiefer, J. A., Henderson, M. C., Trent, J. M., Von Hoff, D. D., and Mousses, S. (2009). Synthetic lethal RNAi screening identifies sensitizing targets for gemcitabine therapy in pancreatic cancer. J. Transl. Med. 7, 43.
5. Blasina, A., Hallin, J., Chen, E., Arango, M. E., Kraynov, E., Register, J., Grant, S., Ninkovic, S., Chen, P., Nichols, T., O'Connor, P., and Anderes, K. (2008). Breaching the DNA damage checkpoint via PF-00477736, a novel small-molecule inhibitor of checkpoint kinase 1. Mol. Cancer Ther. 7, 2394-2404.
6. Bollag, G., Hirth, P., Tsai, J., Zhang, J., Ibrahim, P. N., Cho, H., Spevak, W., Zhang, C., Zhang, Y., Habets, G., Burton, E. A., Wong, B., Tsang, G., West, B. L., Powell, B., Shellooe, R., Marimuthu, A., Nguyen, H., Zhang, K. Y., Artis, D. R., Schlessinger, J., Su, F., Higgins, B., Iyer, R., D'andrea, K., Koehler, A., Stumm, M., Lin, P. S., Lee, R. J., Grippo, J., Puzanov, I., Kim, K. B., Ribas, A., Mcarthur, G. A., Sosman, J. A., Chapman, P. B., Flaherty, K. T., Xu, X., Nathanson, K. L., and Nolop, K. (2010). Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAFmutant melanoma. Nature 467, 596-599.
7. Castedo,M.,Perfettini,J. L.,Roumier,T., Andreau, K., Medema, R., and Kroemer, G. (2004). Cell death by mitotic catastrophe: a molecular definition. Oncogene 23, 2825-2837.
8. Cimini, D., Mattiuzzo, M., Torosantucci, L., and Degrassi, F. (2003). Histone hyperacetylation in mitosis prevents sister chromatid separation and produces chromosome segregation defects. Mol. Biol. Cell 14, 3821-3833.
9. Dai, Y., and Grant, S. (2010). New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin. Cancer Res. 16, 376-383.
10. Dowling, M., Voong, K. R., Kim, M., Keutmann, M. K., Harris, E., and Kao, G. D. (2005). Mitotic spindle checkpoint inactivation by trichostatin a defines a mechanism for increasing cancer cell killing by microtubule-disrupting agents. Cancer Biol. Ther. 4, 197-206.
11. Druker, B. J. (2002). Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML. Oncogene 21, 8541-8546.
12. Esteva, F. J., Yu, D., Hung, M. C., and Hortobagyi, G. N. (2010). Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 7, 98-107.
13. Farmer, H., Mccabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., Martin, N. M., Jackson, S. P., Smith, G. C., and Ashworth,A. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917-921.
14. Gabrielli, B., Chau, Y. Q., Giles, N., Harding, A., Stevens, F., and Beamish, H. (2007). Caffeine promotes apoptosis in mitotic spindle checkpoint-arrested cells. J. Biol. Chem. 282, 6954-6964.
15. Garrett, M. D., and Collins, I. (2011). Anticancer therapy with checkpoint inhibitors: what, where and when? Trends Pharmacol. Sci. 32, 308-316.
16. Gascoigne,K. E.,and Taylor,S. S. (2009). How do anti-mitotic drugs kill cancer cells? J. Cell. Sci. 122, 2579-2585.
17. Giacinti, C., and Giordano, A. (2006). RB and cell cycle progression. Oncogene 25, 5220-5227.
18. Gohler, T., Sabbioneda, S., Green, C. M., and Lehmann, A. R. (2011). ATRmediated phosphorylation of DNA polymerase {eta} is needed for efficient recovery from UV damage. J. Cell Biol. 192, 219-227.
19. Guzi, T. J., Paruch, K., Dwyer, M. P., Labroli, M., Shanahan, F., Davis, N., Taricani, L., Wiswell, D., Seghezzi, W., Penaflor, E., Bhagwat, B., Wang, W., Gu, D., Hsieh, Y., Lee, S., Liu, M., and Parry, D. (2011). Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening. Mol. Cancer Ther. 10, 591-602.
20. Halazonetis, T. D., Gorgoulis, V. G., and Bartek, J. (2008). An oncogene-induced DNA damage model for cancer development. Science 319, 1352-1355.
21. Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
22. Jackson, J. G., Post, S. M., and Lozano, G. (2011). Regulation of tissueand stimulus-specific cell fate decisions by p53 in vivo. J. Pathol. 223, 127-136.
23. Kaelin, W. G. Jr. (2005). The concept of synthetic lethality in the context of anticancer therapy. Nat. Rev. Cancer 5, 689-698.
24. Kaelin, W. G. Jr. (2009). Synthetic lethality: a framework for the development of wiser cancer therapeutics. Genome Med. 1, 99.
25. Kaestner, P., and Bastians, H. (2010). Mitotic drug targets. J. Cell. Biochem. 111, 258-265.
26. Kim, S. Y., Dunn, I. F., Firestein, R., Gupta, P., Wardwell, L., Repich, K., Schinzel, A. C., Wittner, B., Silver, S. J., Root, D. E., Boehm, J. S., Ramaswamy, S., Lander, E. S., and Hahn, W. C. (2010). CK1epsilon is required for breast cancers dependent on beta-catenin activity. PLoS ONE 5, e8979. doi:10.1371/journal.pone.0008979
27. Krauer, K. G., Burgess, A., Buck, M., Flanagan, J., Sculley, T. B., and Gabrielli, B. (2004). The EBNA3 gene family proteins disrupt the G2/M checkpoint. Oncogene 23, 1342-1353.
28. Kuiken, H. J., and Beijersbergen, R. L. (2010). Exploration of synthetic lethal interactions as cancer drug targets. Future Oncol. 6, 1789-1802.
29. Kuntz, K., and O'Connell, M. J. (2009). The G(2) DNA damage checkpoint: could this ancient regulator be the Achilles heel of cancer? Cancer Biol. Ther. 8, 1433-1439.
30. Lapenna, S., and Giordano, A. (2009). Cell cycle kinases as therapeutic targets for cancer. Nat. Rev. Drug Discov. 8, 547-566.
31. Ma, C. X., Janetka, J. W., and Piwnica-Worms, H. (2011). Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. Trends. Mol. Med. 17, 88-96.
32. Malumbres, M., and Barbacid, M. (2009). Cell cycle, CDKs and cancer: a changing paradigm. Nat. Rev. Cancer 9, 153-166.
33. Martin, S. A., Hewish, M., Sims, D., Lord, C. J., and Ashworth, A. (2011). Parallel high throughput RNA interference screens identify PINK1 as a potential therapeutic target for the treatment of DNA mismatch repair deficient cancers. Cancer Res. 71, 1836-1842.
34. McDonald, E. R. III, and El-Deiry, W. S. (2001). Checkpoint genes in cancer. Ann. Med. 33, 113-122.
35. Medema, R. H., and Macurek, L. (2011). Checkpoint control and cancer. Oncogene. doi: 10.1038/onc. 2011.451
36. Morgan, M. A., Parsels, L. A., Zhao, L., Parsels, J. D., Davis, M. A., Hassan, M. C., Arumugarajah, S., Hylander-Gans, L., Morosini, D., Simeone, D. M., Canman, C. E., Normolle, D. P., Zabludoff, S. D., Maybaum, J., and Lawrence, T. S. (2010). Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 70, 4972-4981.
37. Mukhopadhyay, U. K., Senderowicz, A. M., and Ferbeyre, G. (2005). RNA silencing of checkpoint regulators sensitizes p53-defective prostate cancer cells to chemotherapy while sparing normal cells. Cancer Res. 65, 2872-2881.
38. Pavey, S., Conroy, S., Russell, T., and Gabrielli, B. (1999). Ultraviolet radiation induces p16CDKN2A expression in human skin. Cancer Res. 59, 4185-4189.
39. Potratz, J. C., Saunders, D. N., Wai, D. H., Ng, T. L., Mckinney, S. E., Carboni, J. M., Gottardis, M. M., Triche, T. J., Jurgens, H., Pollak, M. N., Aparicio, S. A., and Sorensen, P. H. (2010). Synthetic lethality screens reveal RPS6 and MST1R as modifiers of insulin-like growth factor-1 receptor inhibitor activity in childhood sarcomas. Cancer Res. 70, 8770-8781.
40. Qiu, L., Burgess, A., Fairlie, D. P., Leonard, H., Parsons, P. G., and Gabrielli, B. G. (2000). Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defectiveintumorcells.Mol. Biol. Cell 11, 2069-2083.
41. Rieder, C. L., and Maiato, H. (2004). Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev. Cell 7, 637-651.
42. Scholl, C., Frohling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., Tamayo, P., Wadlow, R. C., Ramaswamy, S., Dohner, K., Bullinger, L., Sandy, P., Boehm, J. S., Root, D. E., Jacks, T., Hahn, W. C., and Gilliland, D. G. (2009). Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834.
43. Sleijfer, S., Wiemer, E., and Verweij, J. (2008). Drug Insight: gastroin-testinal stromal tumors (GIST) - the solid tumor model for cancerspecific treatment. Nat. Clin. Pract. Oncol. 5, 102-111.
44. Sorensen, C. S., Hansen, L. T., Dziegielewski, J., Syljuasen, R. G., Lundin, C., Bartek, J., and Helleday, T. (2005). The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat. Cell Biol. 7, 195-201.
45. Stevens, F. E., Beamish, H., Warrener, R., and Gabrielli, B. (2008). Histone deacetylase inhibitors induce mitotic slippage. Oncogene 27, 1345-1354.
46. Stewart, Z. A., Westfall, M. D., and Pietenpol, J. A. (2003). Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol. Sci. 24, 139-145.
47. Sudo, T., Nitta, M., Saya, H., and Ueno, N. T. (2004). Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint. Cancer Res. 64, 2502-2508.
48. Tse, A. N., Rendahl, K. G., Sheikh, T., Cheema, H., Aardalen, K., Embry, M., Ma, S., Moler, E. J., Ni, Z. J., Lopes De Menezes, D. E., Hibner, B., Gesner, T. G., and Schwartz, G. K. (2007). CHIR-124, a novel potent inhibitor of Chk1, potentiates the cytotoxicity of topoisomerase I poisons in vitro and in vivo. Clin. Cancer Res. 13, 591-602.
49. Warrener, R., Beamish, H., Burgess, A., Waterhouse, N. J., Giles, N., Fairlie, D., and Gabrielli, B. (2003). Tumor cell-selective cytotoxicity by targeting cell cycle checkpoints. FASEB J. 17, 1550-1552.
50. Weaver, B. A., and Cleveland, D. W. (2005). Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 8, 7-12.
51. Zabludoff, S. D., Deng, C., Grondine, M. R., Sheehy, A. M., Ashwell, S., Caleb, B. L., Green, S., Haye, H. R., Horn, C. L., Janetka, J. W., Liu, D., Mouchet, E., Ready, S., Rosenthal, J. L., Queva, C., Schwartz, G. K., Taylor, K. J., Tse, A. N., Walker, G. E., and White, A. M. (2008). AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol. Cancer Ther. 7, 2955-2966.
52. Zhang, C., Yan, Z., Painter, C. L., Zhang, Q., Chen, E., Arango, M. E., Kuszpit, K., Zasadny, K., Hallin, M., Hallin, J., Wong, A., Buckman, D., Sun, G., Qiu, M., Anderes, K., and Christensen, J. G. (2009). PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts. Clin. Cancer Res. 15, 4630-4640.